University of Wisconsin Carbone Cancer Center has been named the newest NCCN Member Institution; NCCN now has 27 Member Institutions serving patients throughout the United States.
The NCCN Foundation has awarded its sixth series of Young Investigator Awards to five oncology researchers from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.
A new study published in the February issue of JNCCN finds that men older than 67 who are diagnosed with prostate cancer are 37 percent more likely to have non-cancer-related hospitalization after diagnosis than before diagnosis, pointing to the need to better manage non-cancer conditions after a cancer diagnosis.
Approximately 1,700 oncology stakeholders are expected to attend NCCN’s 21st Annual Conference: Advancing the Standard of Cancer Care™, March 31 – April 2, 2016, in Hollywood, Florida.
New patient education resources from NCCN empower patients with Chronic Lymphocytic Leukemia and Hodgkin Lymphoma to work alongside their physicians to make informed decisions about their treatment.
NCCN and Pfizer elicited proposals for the development and adoption of evidence-based initiatives to improve patient care and outcomes in metastatic breast cancer; 10 grants were awarded.
NCCN Guidelines with NCCN Evidence Blocks™ for Breast, Colon, Kidney, and Rectal Cancers illustrate five dimensions of value for therapeutic regimens: efficacy, safety, quality and quantity of evidence, consistency of evidence, and affordability.
The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Infinity Pharmaceuticals, Inc. to facilitate studies of duvelisib in the treatment of hematologic malignancies.
Thirty-two researchers from 14 institutions joined forces to identify personalized treatment options for a patient with metastatic triple-negative breast cancer.
The new NCCN Guidelines for Vulvar Cancer are the most comprehensive and up-to-date clinical guidelines available to clinicians today.
The NCCN Oncology Research Program has awarded five research grants to investigate the effectiveness of enzalutamide in mantle cell lymphoma and endometrial, hepatocellular, and prostate cancers.
The NCCN Oncology Research Program has awarded three research grants to investigate the safety and effectiveness of volasertib in hematologic malignancies.
The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to facilitate studies of bavituximab in various cancers.
NCCN is collaborating with Bristol-Myers Squibb to promote the advancement of scientific knowledge concerning programmed death-ligand 1 (PD-L1) protein expression and other immune markers in lung cancer.
The NCCN Foundation welcomes Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH, as the newest representatives to its Board of Directors.
Robert C. Young, MD, has been appointed Interim Vice President of the NCCN Oncology Research Program (ORP).
New visual tool illustrates five dimensions of value within NCCN Guidelines
Press Conference and Media Panel: NCCN Guidelines with NCCN Evidence Blocks: A View of the Patient-Empowered Cancer Conversation
NCCN has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for Kidney Cancer, the newest addition to the library of NCCN Guidelines for Patients.
NCCN is now accepting original abstracts from investigators for consideration for the NCCN 21st Annual Conference General Poster Session; the deadline for submissions is Friday, November 6, 2015.
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to facilitate studies of afatinib in non-small cell lung cancer.
NCCN and Pfizer will elicit grant proposals for quality improvement and education in metastatic breast cancer.
The National Comprehensive Cancer Network® (NCCN®) will host Emerging Issues in Tissue Allocation, on June 8, 2015, at the National Press Club in Washington, DC.
The integration of the NCCN Chemotherapy Order Templates (NCCN Templates®) into the Flatiron Health OncoEMR® electronic health record will allow for access to evidence-based treatment protocols based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
The NCCN Oncology Research Program (ORP) has received a $2-million grant from ImmunoGen, Inc. to facilitate preclinical and clinical research with mirvetuximab soravtansine for Folate Receptor Alpha-positive cancers at NCCN Member Institutions and their affiliate community hospitals.
The NCCN Foundation® has awarded its fifth series of Young Investigator Awards to six oncology researchers from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.
The third and final roundtable of the NCCN 20th Annual Conference explored essential elements of clinical practice guidelines, as well as the historical development of the NCCN Guidelines®.
The fourth annual state oncology society forum, held in conjunction with NCCN’s 20th Annual Conference, examined accountable care, payment reform, and best practices from community oncologists.
Approximately 1,500 oncology representatives attended the NCCN 20th Annual Conference, which featured presentations of the latest developments in the treatment of more than 15 cancer types, as well as three expert roundtable discussions.
The second roundtable discussion of the NCCN 20th Annual Conference explored the concept of value in oncology decision-making, challenging the perceived definition of value and true quality for the patient.
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute has been named the newest NCCN Member Institution; NCCN now has 26 Member Institutions serving patients throughout the United States.
NCCN has published the 20th annual edition of the NCCN Guidelines® for Ovarian Cancer, one of the original NCCN Guidelines published in November 1996.
NCCN has published the 20th annual edition of the NCCN Guidelines® for Acute Myeloid Leukemia, one of the original NCCN Guidelines published in 1996.
Approximately 1,500 oncology stakeholders are expected to attend NCCN’s 20th Annual Conference: Advancing the Standard of Cancer Care™, March 12 – 14, 2015, in Hollywood, Florida.
NCCN has published NCCN Guidelines for Patients®: Acute Lymphoblastic Leukemia (ALL), the newest addition to the library of NCCN Guidelines for Patients®.
Centers for Medicare & Medicaid Services encourages concordance to NCCN Guidelines for Medicare patients in order to achieve better care, smarter spending, and healthier people.
NCCN has published the 20th annual edition of the NCCN Guidelines® for Breast Cancer, one of the original NCCN Guidelines published in November 1996.
January 31, 2015 marks the 20th anniversary of the National Comprehensive Cancer Network; originally announced as an alliance of 13 leading cancer centers in 1995, NCCN has grown to a network of 25 academic cancer centers devoted to patient care, research, and education.
A recent Stanford Cancer Institute study shows that adherence to the NCCN Guidelines® for Colon Cancer in an integrated health care setting improves outcomes in all patients, including minorities.
A new collaboration between NCCN and Flatiron Health will provide the opportunity to analyze key quality and outcomes metrics and identify trends and patterns in the care of patients with cancer.
The NCCN 3D Virtual Simulator Learning Platform allows users to walk through the continuum of care approach to colorectal cancer in a risk-free environment with increasingly complex clinical presentations.
NCCN has published the 20th annual edition of the NCCN Guidelines® for Prostate Cancer, one of the eight original NCCN Guidelines published in November 1996.
NCCN has published the 20th annual edition of the NCCN Guidelines® for NSCLC, one of the eight original NCCN Guidelines published in November 1996.
Printed NCCN Guidelines for Patients® available for order on Amazon.com for Breast (Stages 0 – IV), Colon, and Pancreatic Cancers; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; and Soft Tissue Sarcoma.
The integration of the NCCN Chemotherapy Order Templates (NCCN Templates®) into Epic allows for access to evidence-based treatment protocols based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
NCCN has published the 20th annual editions of the NCCN Guidelines® for Colon and Rectal Cancers, two of the original eight NCCN Guidelines published in November 1996.
On November 3, 2014, NCCN will host its annual Patient Advocacy Summit: Patient Concerns in 2014 – Big Data, Access, and Palliative Care, at The National Press Club in Washington, DC.
As part of the company’s coverage policy development, Cigna is using the NCCN Guidelines® and the NCCN Compendium® as reference in appropriate choice for the treatment of people with cancer in the United States.
The NCCN ORP has awarded four research grants to investigate the effectiveness of nintedanib in non-small cell lung, colorectal, and gastrointestinal cancers.
NCCN is accepting original abstracts from investigators for consideration for the NCCN 20th Annual Conference General Poster Session; Submissions will be accepted from NCCN Member Institutions, academic institutions, teaching and community hospitals, or industry.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right